3C5Z
 
 | |
4P5M
 | | Structural Basis of Chronic Beryllium Disease: Bridging the Gap Between Allergic Hypersensitivity and Autoimmunity | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)][2-acetamido-2-deoxy-beta-D-glucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Wang, Y, Dai, S, Kappler, J. | | Deposit date: | 2014-03-18 | | Release date: | 2014-08-27 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity.
Cell, 158, 2014
|
|
6DFX
 | | human diabetogenic TCR T1D3 in complex with DQ8-p8E9E peptide | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2018-05-15 | | Release date: | 2019-04-17 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.03 Å) | | Cite: | How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes.
Sci Immunol, 4, 2019
|
|
6DFQ
 | | mouse diabetogenic TCR I.29 | | Descriptor: | 1,2-ETHANEDIOL, CALCIUM ION, TCR alpha chain, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2018-05-15 | | Release date: | 2019-04-17 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes.
Sci Immunol, 4, 2019
|
|
6DFV
 | | Mouse diabetogenic TCR 8F10 | | Descriptor: | 1,2-ETHANEDIOL, TCR alpha chain, TCR beta chain | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2018-05-15 | | Release date: | 2019-04-17 | | Method: | X-RAY DIFFRACTION (1.71 Å) | | Cite: | How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes.
Sci Immunol, 4, 2019
|
|
6DFW
 | | TCR 8F10 in complex with IAg7-p8G9E | | Descriptor: | 8F10 alpha chain, 8F10 beta chain, H-2 class II histocompatibility antigen, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2018-05-15 | | Release date: | 2019-04-17 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes.
Sci Immunol, 4, 2019
|
|
6DFS
 | | mouse TCR I.29 in complex with IAg7-p8E9E6ss | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, H-2 class II histocompatibility antigen, A-D alpha chain, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2018-05-15 | | Release date: | 2019-04-17 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | How C-terminal additions to insulin B-chain fragments create superagonists for T cells in mouse and human type 1 diabetes.
Sci Immunol, 4, 2019
|
|
5UJT
 | | Crystal structure of human HLA-DQ8 in complex with insulin mimotope binding in register 3 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose, MHC class II HLA-DQ-beta-1, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2017-01-18 | | Release date: | 2017-12-20 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.94 Å) | | Cite: | C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes.
Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
3C6L
 | |
3C60
 | |
6BLQ
 | | Crystal Structure of IAg7 in complex with insulin mimotope p8E9E | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2017-11-11 | | Release date: | 2017-12-20 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes.
Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BLX
 | | Crystal structure of IAg7 in complex with insulin mimotope p8G9E | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2017-11-11 | | Release date: | 2017-12-20 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.323 Å) | | Cite: | C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes.
Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BLR
 | | Crystal Structure of IAg7 in complex with insulin mimotope p8E9E6SS | | Descriptor: | 1,2-ETHANEDIOL, H2-Ab1 protein, IAg7 alpha chain | | Authors: | Wang, Y, Dai, S. | | Deposit date: | 2017-11-11 | | Release date: | 2017-12-20 | | Last modified: | 2019-12-11 | | Method: | X-RAY DIFFRACTION (1.96 Å) | | Cite: | C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes.
Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
4YK9
 | |
6JQ2
 | | Crystal Structure of H2-Kb in complex with a DPAGT1 self-peptide | | Descriptor: | Beta-2-microglobulin, DPATG1 antigen SIIVFNLV, H-2 class I histocompatibility antigen, ... | | Authors: | Bai, P, Yin, L. | | Deposit date: | 2019-03-28 | | Release date: | 2020-04-01 | | Last modified: | 2021-02-17 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JQ3
 | | Crystal Structure of H2-Kb in complex with a DPAGT1 mutant peptide | | Descriptor: | Beta-2-microglobulin, DPAGT1 mutant antigen SIIVFNLL, H-2 class I histocompatibility antigen, ... | | Authors: | Bai, P, Zhou, Q, Wei, P, Yin, L. | | Deposit date: | 2019-03-28 | | Release date: | 2020-05-06 | | Last modified: | 2021-02-17 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JTN
 | | Crystal structure of HLA-C08 in complex with a tumor mut10m peptide | | Descriptor: | 10-mer peptide, Beta-2-microglobulin, HLA class I antigen, ... | | Authors: | Bai, P, Zhou, Q, Wei, P, Yin, L. | | Deposit date: | 2019-04-11 | | Release date: | 2020-04-15 | | Last modified: | 2021-02-17 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JTP
 | | Crystal structure of HLA-C08 in complex with a tumor mut9m peptide | | Descriptor: | 9-mer peptide, Beta-2-microglobulin, HLA class I antigen, ... | | Authors: | Bai, P, Zhou, Q, Wei, P, Lei, Y. | | Deposit date: | 2019-04-11 | | Release date: | 2020-04-15 | | Last modified: | 2021-02-17 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JTO
 | | Crystal structure of HLA-C05 in complex with a tumor mut10m peptide | | Descriptor: | 10-mer peptide, Beta-2-microglobulin, HLA class I histocompatibility antigen, ... | | Authors: | Bai, P, Zhou, Q, Wei, P, Lei, Y. | | Deposit date: | 2019-04-11 | | Release date: | 2020-04-15 | | Last modified: | 2021-05-19 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Sci China Life Sci, 2021
|
|
6L9K
 | | H2-Ld a1a2 complexed with A5 peptide | | Descriptor: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE | | Authors: | Wei, P.C, Yin, L. | | Deposit date: | 2019-11-10 | | Release date: | 2020-11-18 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9N
 | | H2-Ld complexed with A5 peptide | | Descriptor: | MHC, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, b2m | | Authors: | Wei, P.C, Yin, L. | | Deposit date: | 2019-11-10 | | Release date: | 2020-11-18 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9L
 | | 1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes | | Descriptor: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, T Cell Receptor | | Authors: | Wei, P.C, Yin, L. | | Deposit date: | 2019-11-10 | | Release date: | 2020-11-18 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.399 Å) | | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9M
 | | H2-Ld complexed with AH1 peptide | | Descriptor: | H2-Ld, SER-PRO-SER-TYR-VAL-TYR-HIS-GLN-PHE, b2m | | Authors: | Wei, P.C, Yin, L. | | Deposit date: | 2019-11-10 | | Release date: | 2020-11-18 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
3LQZ
 | | Crystal Structure of HLA-DP2 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, HLA class II histocompatibility antigen, DP alpha 1 chain, ... | | Authors: | Dai, S. | | Deposit date: | 2010-02-10 | | Release date: | 2010-04-14 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (3.25 Å) | | Cite: | Crystal structure of HLA-DP2 and implications for chronic beryllium disease.
Proc.Natl.Acad.Sci.USA, 107, 2010
|
|
